Welcome to the e-CCO Library!

P686: Novel grape-derived prebiotic selectively enhances abundance and metabolic activity of IBD and IBS faecal butyrate producing bacteria in an in vitro model of intestinal fermentation
Year: 2021
Source: ECCO'21 Virtual
Authors: Oliver, L.(1);Ramió-Pujol, S.(1);Amoedo, J.(1);Malagón, M.(1);Serrano, M.(1);Bahí, A.(2);Lluansí, A.(2);Busquets, D.(3);Pardo, L.(3);Serra-Pagès, M.(1);Aldeguer, X.(3);Garcia-Gil, J.(4);
Created: Wednesday, 2 June 2021, 4:12 PM
P686: Outcomes of COVID-19 among patients with inflammatory bowel diseases and the influence of IBD-related medications– A Danish prospective population-based cohort study
Year: 2022
Source: ECCO'22
Authors: Attauabi, M.(1,2,3);Dahlerup, J.F.(4);Poulsen, A.(5);Rosager Hansen, M.(6);Vester-Andersen, M.K.(7);Eraslan, S.(3);Prahm, A.P.(5);Pedersen, N.(8);Larsen, L.(9);Jess, T.(9,10);Neumann, A.(11);Haderslev, K.V.(12);Molazahi, A.(13);Lødrup, A.B.(14);Glerup, H.(15);Oppfeldt, A.M.(16);Jensen, M.D.(17);Theede, K.(1,2);Kiszka-Kanowitz, M.(1,2);Seidelin, J.B.(3);Burisch, J.(1,2);
Created: Friday, 11 February 2022, 3:56 PM
P687 Early and sustained improvement in stool frequency and rectal bleeding following 52 weeks of mirikizumab treatment
Year: 2020
Source:

ECCO'20 Vienna

Authors:

G.R. D’Haens1, T. Hibi2, M. Ferrante3, B.R. Bhandari4, E. Berliba5, J.L. Tuttle6, T. Lissoos7, K. Krueger7, N. Morris7, V. Arora7, A.N. Naegeli7, B.G. Feagan8

Created: Thursday, 30 January 2020, 10:12 AM
P687: Clinical remission demonstrated with oral ozanimod in the overall population and across multiple subgroups of patients with moderately to severely active ulcerative colitis in the TOUCHSTONE trial
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

B. G. Feagan*1, W. J. Sandborn2, G. D'Haens3, S. Hanauer4, D. C. Wolf5, S. Vermeire6, S. Ghosh7, A. Petersen8, S. Y. Hua8, K. Shan8, J. Liu8

Created: Friday, 22 February 2019, 9:41 AM
P687: Development of a panel of microbial markers to distinguish transient from pathological dysbiosis
Year: 2021
Source: ECCO'21 Virtual
Authors: Oliver, L.(1);Ramió-Pujol, S.(1);Malagón, M.(1);Serrano, M.(1);Bahí, A.(2);Busquets, D.(3);Torrealba, L.(3);Serra-Pagès, M.(1);Aldeguer, X.(3);Garcia-Gil, J.(4);
Created: Wednesday, 2 June 2021, 4:12 PM
P687: Durability of recaptured response to ozanimod during the True North open-label extension
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Dignass, A.(1)*;Regueiro, M.(2);Colombel, J.F.(3);Jain, A.(4);Canavan, J.B.(4);Wu, H.(4);Lawlor, G.(4);Osterman, M.T.(4);Vermeire, S.(5);Rubin, D.T.(6);
Created: Friday, 14 July 2023, 11:12 AM
P687: Fate of the rectum in anorectal Crohn's disease
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Zambonin D., Scaringi S., Di Bella A., Giudici F., Bechi P.

Created: Wednesday, 20 February 2019, 10:36 AM
P687: Female sex is associated with discontinuation of subcutaneous anti-TNF therapy for side effects in inflammatory bowel disease
Year: 2018
Source: ECCO '18 Vienna
Authors:

J. Schultheiss*, E. Lamers, E. Brand, H. Fidder

Created: Thursday, 21 February 2019, 9:14 AM
P687: Prevalence of iron deficiency and anaemia in the outpatient Inflammatory Bowel Disease population: a Dutch national cross-sectional study
Year: 2022
Source: ECCO'22
Authors: Loveikyte, R.(1,2);Boer, M.(1);van der Meulen, C.N.(1);ter Steege, R.W.F.(3);Tack, G.(4);Kuyvenhoven, J.(5);Jharap, B.(6);Vu, M.K.(7);Vogelaar, L.(8);West, R.L.(9);van der Marel, S.(10);Römkens, T.(11);Mujagic, Z.(12);Hoentjen, F.(13,14);van Bodegraven, A.A.(15);van Schaik, F.D.M.(16);de Vries, A.C.(17);Dijkstra, G.(2);van der Meulen-de Jong, A.E.(1);
Created: Friday, 11 February 2022, 3:56 PM
P688 Effect of golimumab induction therapy on histologic disease profile in patients with moderate to severe ulcerative colitis: Results from the randomised, placebo-controlled Phase 3 PURSUIT-SC trial
Year: 2020
Source:

ECCO'20 Vienna

Authors:

T. Johansson1, C. Weinstein2, A. MEEHAN3, A. Tzontcheva4, P. Xu4, C. Marano5, G. de Hertogh6

Created: Thursday, 30 January 2020, 10:12 AM
P688: Association of Akkermansia muciniphila with a healthy gut microbiome
Year: 2021
Source: ECCO'21 Virtual
Authors: Ellul, S.(1);Rausch , P.(2);PIsani, A.(3);Bang, C.(4);Ellul, P.(3);Franke, A.(4);
Created: Wednesday, 2 June 2021, 4:12 PM
P688: Crohn's disease patients with a concordant family history are diagnosed earlier and are at increased risk for complicated disease
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Borren N.*1,2, Conway G.1, Garber J.1,3, Khalili H.1,3, Yajnik V.1,3, Xavier R.1,3, Ananthakrishnan A.1,3

Created: Wednesday, 20 February 2019, 10:36 AM
P688: Demographic, clinical, and therapeutic characteristics of a cohort of 238 patients with ulcerative colitis from two medical centres from Uruguay
Year: 2018
Source: ECCO '18 Vienna
Authors:

M.J. Luciano1, A. Noria2, B. Iade1,3*

Created: Thursday, 21 February 2019, 9:14 AM
P688: Patient preferences in medication to treat Ulcerative Colitis: a discrete choice experiment
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Straatmijer, T.(1)*;van den Akker-van Marle, E.(2);van der Horst, D.(3);Scherpenzeel, M.(3);Duijvestein, M.(4);van der Meulen, A.(5);
Created: Friday, 14 July 2023, 11:12 AM
P688: Sex difference in inflammatory bowel disease patients regarding depression: a nationwide population based study in Korea
Year: 2022
Source: ECCO'22
Authors: Moon, J.M.(1);Han, K.(2);Shin, S.Y.(1);Choi, C.H.(1);Kim, J.S.(3);
Created: Friday, 11 February 2022, 3:56 PM
P688: Ustekinumab in resistant Crohn’s disease: 1-year UK IBD tertiary referral centre ‘real-world’ experience
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

S. P. Borg-Bartolo*1, K. Kemp1, R. P. Willert1, A. J. Makin1, S. E. Levison1

Created: Friday, 22 February 2019, 9:41 AM
P689 Patient-reported outcomes (PRO-2) and intestinal ultrasound in ulcerative colitis patients: subanalysis of the TRUST&UC study cohort
Year: 2020
Source:

ECCO'20 Vienna

Authors:

C. Maaser1, U. Helwig2, I. Fischer3, S. Rath4, S. Kolterer4, T. Kucharzik5

Created: Thursday, 30 January 2020, 10:12 AM
P689: Aeromonas infection and Inflammatory Bowel Disease: a single tertiary center analysis
Year: 2021
Source: ECCO'21 Virtual
Authors: Alves Da Silva, J.(1);Pereira Guedes, T.(1);Falcão, D.(1);Neves, S.(2);Costa, P.(3);Lago, P.(1);Pedroto, I.(1);Salgado, M.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P689: Biologics utilization in children with inflammatory bowel diseases is higher and earlier than in adults: a report from the epi-IIRN group
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Friedman M.*1, Axelrod R.1,2, Rosenblum J.3, Zigman N.3, Goren I.3, Lederman N.4, Cohen N.4, Matz E.5, Dushnitzky D.5, Borovsky N.5, Gavish M.2, Focht G.1, Avitzour M.1, Dotan I.6, Benchimol E.7, Turner D.1

Created: Wednesday, 20 February 2019, 10:36 AM
P689: Multicenter, cross-sectional, observational study on Epstein–Barr viral infection status and thiopurine use by age group in patients with inflammatory bowel disease in Japan
Year: 2022
Source: ECCO'22
Authors: Miura, M.(1);Shimizu, H.(2);Saito, D.(1);Miyoshi, J.(1);Matsuura, M.(1);Kudo, T.(3);Hirayama, D.(4);Yoshida, M.(5);Arai, K.(2);Iwama, I.(5);Nakase, H.(4);Shimizu, T.(3);Hisamatsu, T.(1);
Created: Friday, 11 February 2022, 3:56 PM